RCUSArcus Biosciences, Inc.
$18.95-3.9% 1Y
$18.95
$17.6952 weeks$31.57
The business
How RCUS's business earns
Arcus Biosciences, Inc. spent more than it took in: an operating loss of $475M on $100M of revenue, 12 months to Sep 30, 2026.
$475M
Operating loss · on $100M of revenue · 12 months to Sep 30, 2026
- Share count, year on year
- +20%
Share count, year on year · more shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2020 | −159% |
| FY2021 | 14% |
| FY2022 | −250% |
| FY2023 | −291% |
| FY2024 | −128% |
| FY2025 | −156% |
Details›
- Operating margin12 months to Sep 30, 2026
- −475%
- Net margin12 months to Sep 30, 2026
- −453%
- Free cash flow margin
- −466%
- R&D as % of revenue
- 473%
- Revenue, trailing twelve months
- $100M
- Free cash flow, trailing twelve months
- −$466M
- Net income, trailing twelve months
- −$453M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from RCUS and who it buys from, as the companies report it.
97%of revenue comes from Gilead Sciences
Customerswho buys
- GILDGilead Sciences97%
Share of revenue · FY2025 10-K
Supplierswho it buys from
None disclosed.
Biotechnology
The closest names by size in the same industry